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Conventional regimens have limited impact against non-small cell lung cancer (NSCLC). Current research is focusing on multiple
pathways as potential targets, and this study investigated molecular mechanisms underlying the combination of the PKCb inhibitor
enzastaurin with the multitargeted antifolate pemetrexed in the NSCLC cells SW1573 and A549. Pharmacologic interaction was
studied using the combination-index method, while cell cycle, apoptosis induction, VEGF secretion and ERK1/2 and Akt
phosphorylation were studied by flow cytometry and ELISAs. Reverse transcription–PCR, western blot and activity assays were
performed to assess whether enzastaurin influenced thymidylate synthase (TS) and the expression of multiple targets involved in
cancer signaling and cell cycle distribution. Enzastaurin-pemetrexed combination was highly synergistic and significantly increased
apoptosis. Enzastaurin reduced both phosphoCdc25C, resulting in G2/M checkpoint abrogation and apoptosis induction in
pemetrexed-damaged cells, and GSK3b and Akt phosphorylation, which was additionally reduced by drug combination ( 58% in
A549). Enzastaurin also significantly reduced pemetrexed-induced upregulation of TS expression, possibly through E2F-1 reduction,
whereas the combination decreased TS in situ activity (450% in both cell lines) and VEGF secretion. The effects of enzastaurin on
signaling pathways involved in cell cycle control, apoptosis and angiogenesis, as well as on the expression of genes involved in
pemetrexed activity provide a strong experimental basis to their evaluation as pharmacodynamic markers in clinical trials of
enzastaurin-pemetrexed combination in NSCLC patients.
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Non-small cell lung cancer (NSCLC) is one of the most commonly
occurring malignancies worldwide for which platinum-based
regimens are standard first-line treatment (Buter and Giaccone,
2005). However, the dose-limiting toxicity profile of these
regimens, as well as response rates not exceeding 40%, warrant
novel strategies and new combination regimens against NSCLC.
The multitargeted antifolate pemetrexed is approved as a single
agent in second-line treatment of patients with locally advanced or
metastatic NSCLC after earlier chemotherapy (Hanna et al, 2004).
It inhibits three of the enzymes essential for purine and pyrimidine
synthesis; dihydrofolate reductase (DHFR), glycinamide ribonu-
cleotide formyl transferase, and thymidylate synthase (TS), the
latter being the most important target (Hanauske et al, 2001).
However, resistance to pemetrexed may develop (Peters et al,
2005), and hence combinations with other anticancer agents are
important to investigate.
Enzastaurin, a novel targeted agent, selectively inhibits PKCb by
interacting competitively at its ATP-binding site (Faul et al, 2003).
Because of its pivotal role in the regulation of tumour-induced
angiogenesis, cell cycle progression, tumour cell proliferation,
survival, and tumour invasiveness, PKCb is recognised as an
important target for cancer treatment (Goekjian and Jirousek,
2001; Liu et al, 2004). Enzastaurin was originally evaluated in
human tumour xenograft-bearing mice for its antiangiogenic
activity upon PKCb inhibition, as it showed reduction of plasma
VEGF levels together with a significant decrease in intratumoural
vessel density (Keyes et al, 2004). However, several studies have
shown that enzastaurin exhibits direct growth inhibiting effects on
a wide array of cultured human tumour cells (Graff et al, 2005;
Oberschmidt et al, 2005; Querfeld et al, 2006; Rizvi et al, 2006;
Podar et al, 2007; Spalding et al, 2007; Lee et al, 2008). Recent
studies suggest that the antitumour effects of enzastaurin are
mediated through interference with the phosphatidylinositol
3-kinase (PI3K)/Akt pathway (Graff et al, 2005; Querfeld et al,
2006; Rizvi et al, 2006; Lee et al, 2008), an important pathway
regulating the apoptotic response.
The advantage of enzastaurin and other targeted agents is that
they can act selectively on inappropriately expressed or over-
expressed molecules in cancer signaling pathways. Overexpression
of different PKC isoforms has been detected in NSCLC cells and
Received 30 April 2008; revised 15 July 2008; accepted 23 July 2008;
published online 19 August 2008
*Correspondence: Professor GJ Peters, Department of Medical
Oncology, VU University Medical Center, Cancer Center Amsterdam,
De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;
E-mail: gj.peters@vumc.nl
4These authors equally contributed to the study.
British Journal of Cancer (2008) 99, 750–759
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
stumour tissues (Clark et al, 2003; Lahn et al, 2006), whereas
activation of Akt was associated with significantly worse 5-year
survival rate in NSCLC patients (Tang et al, 2006).
Currently enzastaurin is being evaluated in several clinical trials
and tolerability and survival data obtained in a recent phase II trial
as second- or third-line therapy in NSCLC suggest further
evaluation in combination with cytotoxic drugs (Oh et al,
2008). Indeed other studies have demonstrated the safety of
enzastaurin combination with conventional chemotherapy
(Hanauske et al, 2006; Rademaker-Lakhai et al, 2007), and the
inhibition of selected targets, including PKCb, can enhance the
effect of cytotoxic drugs, such as pemetrexed. Previous studies
showed positive synergism for this combination in thyroid and
lung cancer cell lines (Oberschmidt et al, 2005; Nakajima et al,
2006), but data on possible molecular mechanisms or biomarkers
of that combination are still lacking.
The aim of this study was to investigate the main pharmaco-
logical aspects of the enzastaurin-pemetrexed combination in
NSCLC cells. For this purpose the potential synergistic interaction,
as well as the responsible mechanisms were studied.
MATERIALS AND METHODS
Drugs and chemicals
Both pemetrexed and enzastaurin were provided by Eli Lilly
Corporation (Indianapolis, IN, USA). The drugs were dissolved in
Hanks’ balanced salt solution and Dimethyl Sulphoxide (DMSO)
respectively, stored at  201C, and diluted in culture medium
immediately before use. (5-
3H)-Deoxycytidine and (5-
3H)-
DeoxyUMP were from Moravek Biochemicals (Brea, CA, USA).
All other chemicals were of analytical grade.
Cells and culture conditions
The NSCLC cell lines A549 (adenocarcinoma) and SW1573
(alveolar carcinoma) were from American Type Culture Collection
(ATCC) (Manassas, VA, USA), and were cultured in Dulbecco’s
modified Eagle’s medium (Flow Laboratories Irvine, Scotland),
supplemented with 10% heat-inactivated Fetal calf serum, 20mM 2-
(4-(2-Hydroxyethyl)-1-piperazinyl)-ethanesulphonic acid, and 1%
penicillin–streptomycin (Gibco Paisley, UK), at 371C under an
atmosphere of 5% CO2. The cells were maintained in 75cm
2 tissue
culture flasks (Greiner Bio-One GmbH, Frickenhausen, Germany)
and were harvested with trypsin-EDTA (Invitrogen, Paisley, UK) in
their exponentially growing phase.
Growth inhibition and drug combination studies
Growth inhibitory effects of pemetrexed and enzastaurin were
evaluated with the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay, which measures mitochondrial
activity of viable cells. both cell lines (3000 cells per well) were
plated into flat bottom 96-well plates (Greiner Bio-One GmbH,
Frickenhausen, Germany) and allowed to attach for 24h. The cells
were treated for 72h as follows: (1) a concentration range (0.01–
50mM) of the indicated drugs to determine the IC50 values;
(2) simultaneous combination of the two drugs using a fixed
IC50-based molar ratio; (3) simultaneous combination using a
variable ratio (with constant IC25 concentration of enzastaurin);
(4) sequential combination using a variable ratio. After treatment,
the medium was removed and cells were incubated for 3h at 371C
in 50ml per well MTT solution (final concentration 0.42mgml
 1).
Formazan crystals formed were dissolved in 150ml per well DMSO
and the absorbance was measured at 540nm using a spectro-
photometric microplate reader (Tecan Spectrafluor, Salzburg,
Austria). Absorbance values were corrected for the absorbance at
the day of drug administration, which was taken as 0%, the
difference with untreated controls was set at 100%, and the effect
of drugs as a percentage thereof. The 50% inhibitory concentration
of cell growth was estimated from the logarithmic growth
inhibition curves.
The pharmacological interaction of enzastaurin and pemetrexed
was assessed using the multiple drug effect analysis based on the
methods described by Chou and Talalay (1984) in which a
Combination Index (CI)o0.9, 0.9–1.1 and 41.1 indicate syner-
gism, additivity and antagonism, respectively. The mean CI was
calculated from all data points with fraction affected (FA)40.5, as
values lower were not considered relevant for growth inhibition
(Peters et al, 2000). The data were processed by the Calcusyn
Software (Biosoft, Cambridge, UK), which calculates the CI of the
combination based on the effect of the growth inhibition caused by
the drugs alone relative to the effect produced by the combination.
Cell cycle and apoptosis analysis
Flow cytometry was used to determine cell cycle distribution as
well as the amount of apoptotic cells within the cell populations
exposed to the drugs alone or in combination as described
previously (Temmink et al, 2007). Cells at a density of 50 10
3
cells per well were plated into flat bottom 6-well plates (Greiner
Bio-One GmbH, Frickenhausen, Germany) and allowed to attach
for 24h prior to drug treatments at IC50 concentrations. The
exposure time ranged from 24–72h involving both single drug
treatments as well as simultaneous combination drug treatments.
Subsequently, adherent and floating cells were harvested and
counted, and at a concentration of 1 10
5cellsml
 1 transferred to
round-bottom FALCON tubes (BD, Franklin Lakes, NJ, USA). After
centrifugation, the cell pellets formed were gently resuspended in
1.0ml hypotonic propidium iodide (PI)-solution (50mgml
 1 PI,
0.1% sodium citrate, 0.1% Triton X-100, 0.1mgml
 1 ribonuclease
A) and the samples were stored on ice for 30min. Cell cycle
analyses were performed using a FACScan (BD Biosciences, Mount
View, CA, USA) and the data analysis was carried out with
CELLQuestt software, using gates on DNA histograms to estimate
the amount of cells in G1, S, and G2/M phases, as well as the
apoptotic cells in the sub-G1 region.
Real-time PCR
To evaluate the effect of 24-h treatment with IC50 levels of
enzastaurin, pemetrexed and their combination on the expression
levels of molecules involved in drug activity, cell cycle control and
angiogenesis we studied the mRNA expression of TS, E2F-1 and
VEGF. RNA was extracted by the QiaAmp RNA mini-Kit (Qiagen,
San Diego, CA, USA), and reverse transcribed. Forward and
reverse primers and probes were designed with Primer Express
(Applied Biosystems, Foster City, CA, USA) on the basis of TS gene
sequence (Giovannetti et al, 2005), whereas primers and probes for
E2F-1, and VEGF were obtained from Applied Biosystems Assay-
on-Demand Gene expression products (Hs001572991_m1, and
Hs00173626_m1). Amplification data were normalised to b-actin,
and quantification of gene expression was performed using
standard curves obtained with dilutions of cDNA from Quantita-
tive-PCR Human-Reference Total-RNA (Stratagene, La Jolla, CA,
USA).
Western blot analysis
Enzastaurin and pemetrexed and their combination were also
studied for their ability to modulate protein expression of different
possible targets or surrogate markers of drug activity by western
blot analyses. Frozen pellets of A549 and SW1573 cells previously
treated with IC50 concentrations of pemetrexed and enzastaurin
(single and in the simultaneous combination) for 24h were
resuspended in a lysis buffer (0.1% (v/v) Triton X-100, 10%
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sglycerol, 150mM NaCl, 10mM Tris-HCL pH 7.6, 50mM
b-glycerophosphate, and 5mM EDTA). Protein content was
assessed using the BioRad assay, whereas SDS–PAGE was
performed as described earlier (Sigmond et al, 2003). Briefly,
whole cell lysates were denatured in sample buffer containing SDS
and b-mercaptoethanol, and equal amounts of total protein were
separated on 10–15% SDS–poly-acrylamide gels and transferred
to polyvinylidene fluoride membranes. After blocking with 5%
nonfat dry milk/TBST, the membranes were incubated overnight at
41C with the primary antibodies diluted in 5% BSA/TBST. The
following antibodies were used: anti-phospho-Akt (Ser473)
1:1000, anti-Akt 1:1000, anti-MAPK 1:1000, anti-phospho-
GSK3b (Ser9) 1:1000, anti-GSK3b 1:1000, anti-phospho-Cdc25C
(Ser216) 1:1000, anti-Cdc25C 1:1000, anti-phospho-CDK2 (Thr
160) 1:1000, anti-CDK2 1:1000, anti-CDK4 1:2000 (all from Cell
Signaling Technology Inc., Danvers, MA, USA), anti-E2F-1 1:100,
anti-PKCb 1:500, anti-COX-2 1:2000 (all from Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), anti-TS 1:1000
(Provided by Dr GW Aherne, Institute for Cancer Research,
Sutton, UK) (van Triest et al, 2000), and as a loading control anti-
b-actin 1:10000 (Sigma-Aldrich, St Louis, MO, USA). The
subsequent day, the membranes were incubated with the appro-
priate horseradish peroxidase-conjugated secondary antibodies,
and detection was performed using chemiluminescence reagent
(GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA) according
to the manufacturer’s protocol.
ERK1/2 and Akt phosphorylation assays
To study the effect of drug treatments on the activation of ERK1/2
and Akt, cells were exposed to IC50s of enzastaurin, pemetrexed
and enzastaurin-pemetrexed combination for 24h. After protein
extraction from cell pellets, the dual-phosphorylation of ERK2 at
threonine 185 and tyrosine 187 (ERK2 (pTpY185/187)) and ERK1
at threonine 202 and tyrosine 204 (ERK1 (pTpY202/204)) and Akt
phosphorylation at serine residue 473 (Akt (pS473)), were
evaluated with specific ELISA assays (BioSource International,
Camarillo, CA, USA), and normalised respectively to the total
EGFR, ERK1/2 and Akt and protein content (Giovannetti et al,
2008).
VEGF levels
Measurement of VEGF levels in medium was performed after
exposing 1 10
5 cells to IC50 concentrations of the drugs alone and
in combination. Samples of the medium (200ml) were taken after
24h, centrifuged for 20min at 1000g and immediately frozen until
analysis. Vascular endothelial growth factor levels were measured
using a specific ELISA kit (R&D diagnostics, Minneapolis, USA)
according to the instructions of the manufacturer. A calibration
line was included in each plate.
Evaluation of TS activity
To evaluate the possible modulation of TS in situ activity, we
determined its potential inhibition in intact cells, after 24h drug
exposure at IC50s. For this purpose cells were plated at 0.25 10
6
cells in 6-well plates. After 22h of drug treatment (5-
3H)-
deoxycytidine (0.3mM, final specific activity 1.6Cimmol
 1) was
added. After uptake, (5-
3H)-deoxycytidine was phosphorylated to
(5-
3H)-dCMP, which was deaminated to (5-
3H)-dUMP, which was
in turn methylated to dTMP releasing
3H2O. Production of
3H2O
was measured by collecting medium samples after 2h and
counting of the radioactivity as described (Rots et al, 1999).
Furthermore, to study the direct effect of enzastaurin and
pemetrexed on TS we also measured TS catalytic activity in
extracts of SW1573 and A549 cells at 1 or 10mM (5-
3H)dUMP, as
described earlier (Sigmond et al, 2003).
RESULTS
Growth inhibition studies of pemetrexed and enzastaurin
A dose-dependent inhibition of cell growth was observed with
pemetrexed and enzastaurin (Figure 1), with IC50 values of 0.05
and 21.75mM (SW1573) and 0.19 and 8.83mM (A549), respectively
(Table 1). As the CI method recommends a ratio of concentrations
at which drugs are equipotent, the following combination studies
were performed using fixed ratios with IC50 values calculated from
the previous cytotoxicity analysis for the different drug treatments
in each cell line (i.e., 1:50 and 1:450 in A549 and SW1573 cells,
respectively). However, as enzastaurin is administered orally
(Carducci et al, 2006) and reaches a relatively stable plasma
concentration for a prolonged time, we also used enzastaurin at a
fixed IC25 concentration in simultaneous combination in both cell
lines and in the sequential combination in the less sensitive
SW1573 cells.
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Figure 1 Cytotoxicity and pharmacological interaction of enzastaurin and
pemetrexed. Representative curves of growth inhibitory effects of pemetrexed
and sequential (24-h enzastaurin followed by 48-h pemetrexedþenzastaurin
exposure) drug combination (A) and simultaneous enzastaurin-pemetrexed
combination (B) in SW1573 cells, using a variable ratio (with constant IC25
concentration of enzastaurin). Points and columns, mean values obtained from
three independent experiments; bars, s.e.
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sBoth the simultaneous and the sequential combination reduced
the IC50 values of pemetrexed in the studied cell lines.
Representative growth inhibition curves for SW1573 cells are
shown in Figure 1A and B. The multiple drug effect analysis
revealed strong synergistic effects in the simultaneous treatment as
well as in the sequential schedule. In particular, the CI plots of
simultaneous combination in both cells showed a clear synergistic
interaction at the more relevant FA values (X50%). The average CI
values for enzastaurin-pemetrexed combinations in the two
NSCLC cell lines are summarised in Table 1.
To evaluate the mechanisms underlying the synergistic interac-
tion in both cell lines, several biochemical analyses were
performed with the simultaneous combination, as detailed
below.
Cell cycle distribution
DNA flow cytometry studies were performed to evaluate the effect
of enzastaurin, pemetrexed and their combinations on the cell
cycle distribution and to determine whether their cell cycle
modulating activity might provide clues to optimise drug
scheduling. Both agents were able to affect the cell cycle of the
studied NSCLC cells (Figure 2A and B).
Pemetrexed treatment resulted in a 1.3 to 1.9-fold increase in the
percentage of cells in the S-phase after 24h in SW1573 and A549
cells, respectively. The increment in S-phase was most pronounced
after 72h, with 37 and 39% of the SW1573 and A549 cells arrested
in the S-phase. In contrast, the 24h enzastaurin treatment caused
minimal perturbations in the A549 cells, and a 1.5-fold increase in
the percentage of SW1573 cells in the G2/M phase. In both cell
lines enzastaurin led to 1.3-fold increase in the G1 phase at 72h.
However, the simultaneous combination at 72h resulted in a G2/M
phase increase in both cell lines. In particular, the increase in the
G2/M phase cell population was most pronounced in A549 cells
(from 25 to 43% in control and treated cells respectively), whereas
SW1573 cells showed a 1.5-fold enhancement.
Apoptosis
The extent of apoptosis induction was investigated as the
accumulation of cells with sub- G1 DNA content in FACS analysis,
and was time-dependent in both cell lines, with minimal changes at
24h. After 72h enzastaurin slightly increased the percentage of
apoptotic cells in SW1573 cells (Figure 2C), whereas a significant
increase with respect to control was observed in A549 cells
(Figure 2D). Pemetrexed induced more apoptosis than enzastaurin
in both cell lines, ranging from 10.8 to 14.0% in SW1573 and A549
cells, respectively (Po0.01 vs control). The combination showed a
more than additive cell kill with respect to the single drugs and a
significant induction in apoptosis compared with both controls
and pemetrexed-treated cells (Po0.001 vs control and Po0.05 vs
pemetrexed).
Modulation of signal transduction
Since enzastaurin affects several intracellular signaling cascades,
we initially focused on expression of different proteins down-
Table 1 Cytotoxic effect and pharmacological interaction of enzastaurin and pemetrexed in NSCLC cell lines
IC50 (lM)
a CI
b
Cell line Enzastaurin Pemetrexed Simultaneous fixed ratio Simultaneous variable ratio Sequential variable ratio
SW1573 21.75±1.97 0.05±0.1 0.56±0.07 0.09±0.02 0.25±0.035
A549 8.83±1.59 0.19±0.2 0.3±0.06 0.03±0.01
c
aIC50 concentrations of the two drugs were calculated as mean values±s.e.m. of at least three independent experiments.
bCI values of simultaneous and sequential enzastaurin-
pemetrexed combination at FA of 0.5, 0.75 and 0.9 were averaged for each experiment, and this value was used to calculate the mean between experiments, as described in the
Materials and methods section.
cNo CI value for this cell line, as A549 cells were less sensitive to pemetrexed compared with the SW1573 cells, and the 48-h exposure to
pemetrexed, in the concentration range used in our study, was not enough cytotoxic to allow the correct calculation of the CI values in the enzastaurin (24h) -
pemetrexed+enzastaurin (48h) sequential schedule.
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Figure 2 Cell cycle modulation and apoptosis induction. Effects of
enzastaurin, pemetrexed and their simultaneous combination on the cell
cycle distribution in SW1573 (A) and A549 cells (B) after 72h exposure to
their IC50 values. Apoptosis (%) induced by enzastaurin, pemetrexed and
the simultaneous combination in SW1573 (C) and A549 (D) cells after 24
and 72h time points. Values (%) are means from three independent
experiments±s.e.m. Columns (%), mean values obtained from three
independent experiments; bars, s.e.; *Po0.05 with respect to control cells,
#Po0.05 with respect to pemetrexed-treated cells.
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sstream of PKCb (Figure 3A). Western blot analyses did not show
significant modulation in the expression of PKCb in both A549 and
SW1573 cells treated with enzastaurin, pemetrexed and their
simultaneous combination. Similarly total MAPK and total Akt
were not affected by drug treatments. However, the expression of
the target downstream of Akt, GSK3b was reduced by enzastaurin
in both cell lines. In contrast, pemetrexed reduced GSK3b
expression in the SW1573 cells whereas an unexpected relevant
increase with respect to control was observed in A549 cells.
However, the enzastaurin-pemetrexed combination resulted in a
slight reduction of GSK3b expression in A549 cells. Furthermore,
enzastaurin completely suppressed the phosphorylation of GSK3b
in both cell lines. Likewise, GSK3b
ser9 was inhibited by the
combination even to undetectable levels (Figure 3A).
Phosphorylation of GSK3b
ser9 has been repeatedly linked to Akt
activity. Indeed the suppression of GSK3b
ser9 may reflect the
inhibition of PKCs as well as of the Akt pathway. Consistent with
the latter possibility, the ELISA assays showed that enzastaurin
significantly reduced the Akt phosphorylation at the serine residue
pS473, and therefore the phospho-Akt/total Akt ratio, in both cell
lines (Figure 3B). A lower, but still significant decrease in
phospho-Akt was also induced by pemetrexed. Finally, Akt
phosphorylation status was additionally reduced by the simulta-
neous combination of enzastaurin and pemetrexed, with a degree
of inhibition of 68 and 62% in A549 and SW1573 cells, respectively.
These data are in agreement with our previous results, showing the
highest apoptosis induction in cells treated with drug combination.
PKC activation can also trigger signaling through the ERK
pathway, which may also be involved in the control of cellular
proliferation and death. Enzastaurin resulted in a significant
inhibition of pERK1/2 in both cell lines, whereas pemetrexed
slightly increased ERK1/2 phosphorylation (Figure 3B). A reduc-
tion of phospho-ERK1/2, less pronounced than the one observed
with enzastaurin alone, but still significant with respect to controls,
was also detected after the drug combination.
Modulation of cell cycle proteins and TS
As PKCs regulate cell cycle progression by phosphorylation
(directly or indirectly) of cell cycle-dependent kinases and
transcription factors, we evaluated the expression of several of
these proteins by western blot analysis (Figure 4A). Our findings
suggest that enzastaurin might affect the cell cycle at both the G2/
M and G1/S checkpoints. In particular, enzastaurin resulted in a
marked decrease of both total and phosphorylated Cdc25C in both
cell lines, as shown in a representative example in Figure 4A. The
dephosphorylation of Cdc25C induces G2-M transition. Hence,
enzastaurin treatment might abrogate the G2/M checkpoint.
Consequently, cells with DNA damage (due to pemetrexed
treatment) can progress in the cell cycle and eventually undergo
apoptosis.
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Figure 3 Modulation of cell signaling pathways. (A) Modulation of
protein expression of different targets involved in cell signaling pathways by
enzastaurin, pemetrexed and their simultaneous combination (24h to IC50
values). The western blots shown are representative of 2–3 separate
experiments, loading 20mg protein. Modulation of Akt (B), and ERK1/2 (C)
phosphorylation by enzastaurin, pemetrexed and their simultaneous
combination, for 24h, at IC50 values, in NSCLC cells, as determined with
ELISA assays. Columns, mean values obtained from three independent
experiments; bars, s.e. *Significantly different from controls (Po0.05).
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Figure 4 Effects of enzastaurin and pemetrexed on the expression of
different targets involved in cell cycle regulation. (A) Modulation of protein
expression of different targets involved in cell cycle by enzastaurin,
pemetrexed and their simultaneous combination (24h to IC50 values); (B)
Modulation of E2F-1 and TS mRNA expression as determined by real-time
PCR; and (C) modulation of TS in situ activity. The TS in situ activity values
were calculated as percentages of values obtained in control cells (i.e., 215
and 321pmol/h/10
6 cells in A549 and SW1573 cells, respectively). The
blots shown are representative of 2–3 separate experiments, loading 20mg
protein. *Significantly different from controls (Po0.05).
#Significantly
different from cells treated with pemetrexed (Po0.05).
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sEnzastaurin did not affect CDK2 and CDK4 (data not shown),
but was able to downregulate the S-phase regulator E2F-1 and
possibly influenced the G1/S checkpoint. Indeed, our results
suggest that enzastaurin has a direct effect on E2F-1, which
regulate in turn the transcription of several genes, including TS.
E2F-1 mRNA expression was significantly reduced by enzastaurin
treatment, whereas pemetrexed increased E2F-1 mRNA levels
(Figure 4B). However, a significant reduction of E2F-1 mRNA
expression was also detected after the drug combination in both
cell lines. These results were consistent with those of Figure 4A,
showing that pemetrexed increased E2F-1 protein expression,
whereas E2F-1 protein levels were significantly reduced by
enzastaurin and the enzastaurin-pemetrexed combination.
As TS expression has been correlated with pemetrexed activity
both in the preclinical and in the clinical settings, the present study
also investigated the changes in TS mRNA and protein expression
as well as in TS activity in treated cells. In comparison with the
respective controls, both the A549 and the SW1573 cells treated
with enzastaurin were characterised by a significant reduction in
TS mRNA, whereas pemetrexed markedly increased TS mRNA
(Figure 4B). However, a significant reduction in TS mRNA
expression was also detected after enzastaurin-pemetrexed simul-
taneous combination in A549 cells, whereas a lower degree of
inhibition ( 28%) was detected in SW1573 cells. Thymidylate
synthase expression was also studied at the protein level, by
western blotting analysis, which revealed that enzastaurin and
pemetrexed affected TS protein expression in both NSCLC cells
(Figure 4A). In particular, a strong induction was detected in A549
and SW1573 pemetrexed-treated cells, whereas the faintest bands
were observed in the extracts of enzastaurin-treated cells.
Furthermore, enzastaurin was able to reduce the upregulation of
TS caused by pemetrexed, as detected in the cells treated with the
enzastaurin-pemetrexed combination.
As protein expression of TS is not always predictive for the real
enzymatic activity in the cells, we then evaluated TS activity by the
TS in situ assay, in which intact cells are used, and the drugs are
still present in the cells, resulting in an actual measurement of real
intracellular TS inhibition (Figure 4C). This assay showed a clear
inhibition of TS by pemetrexed and enzastaurin in both cell lines.
Most interestingly, the combination almost completely inhibited
the TS activity in situ (i.e., 13±2 and 9±4% in SW1573 and A549
cells, respectively) and statistical analysis revealed significant
reductions with respect to those observed after pemetrexed
exposure.
Direct inhibition of TS activity by nzastaurin was excluded as
addition of enzastaurin up to 50mM did not inhibit TS activity in
extracts of both cell lines, whereas FdUMP and pemetrexed, used
as a control, showed similar inhibition as reported earlier (Van
Triest et al, 1999).
Effects on COX-2 and VEGF
As enzastaurin has been reported to have an anti-VEGF effect we
evaluated the expression of possible markers of antiangiogenic
activity both in cells and in cell culture medium.
In particular, we investigated the expression level of the pro-
angiogenic factor COX-2 to determine whether it could serve as a
reliable marker of the antiangiogenic effect of enzastaurin in
NSCLC cells. However, no expression of COX-2 was found in the
SW1573 cell line. Furthermore in the A549 cells the expression
levels were still elevated after drug exposure, indicating that the
antiangiogenic effects of enzastaurin might not be because of
modulation of the COX-2 enzyme in the studied cell lines
(Figure 5A).
On the other hand, enzastaurin significantly decreased both
VEGF mRNA expression and VEGF secretion into the medium.
Pemetrexed induced a slight increase of VEGF expression (Figure
5B and C). However, the combination induced a significant
inhibition of VEGF expression. In line with this, VEGF secretion
was significantly reduced after enzastaurin-pemetrexed combina-
tion in both cell lines (Figure 5C).
DISCUSSION
In this study we found that the interaction between enzastaurin
and pemetrexed was highly synergistic in NSCLC cells. These
results are in agreement with previous data obtained with
pemetrexed-enzastaurin combination both in lung and in thyroid
cancer cells (Oberschmidt et al, 2005).
The synergistic activity of enzastaurin was detected in all the
studied combinations, at concentrations similar to those achieved
in clinical trials (Rademaker-Lakhai et al, 2007).
These findings are of importance as pemetrexed is already
registered for treatment of NSCLC, and enzastaurin might be a
promising agent to improve the effect of pemetrexed in NSCLC
patients, possibly as an alternative to cisplatin regimens. Unlike
EGFR-tyrosine kinase inhibitors, antiangiogenic agents combined
with conventional chemotherapy have demonstrated clinical
benefit in NSCLC (Herbst et al, 2007), and recent studies have
demonstrated the safety of enzastaurin combination with cytotoxic
drugs (Rademaker-Lakhai et al, 2007), including pemetrexed
(Hanauske et al, 2006).
Furthermore, our findings are novel because they show that the
synergistic interaction seems to be mediated by several mechan-
isms, summarised in Figure 6, which enhanced the sensitivity
to pemetrexed and should be used as predictive biomarkers
for the future clinical development of enzastaurin-pemetrexed
combination.
Several studies have shown the importance of modulating the
cell cycle to exploit the effect of drug combinations (Schwartz and
Shah, 2005). Drugs interacting at different sites in the cell cycle
might potentiate the therapeutic response. In this study, FACS
analysis demonstrated that pemetrexed caused an S-phase arrest,
as previously detected in different tumour cell lines (Tonkinson
et al, 1997, 1999; Giovannetti et al, 2005). In contrast, enzastaurin
alone increased the percentage of cells in the G1 phase, whereas in
the combination the cells accumulated in G2/M phase. These
results are in agreement with previous studies showing that PKCs
mediate the regulation of the cell cycle (Fishman et al, 1998; Black,
2000). In particular, the phosphorylation mediated by PKC might
activate Cdc25C, which is an important control component of the
G2/M checkpoint (Yu et al, 2004). This inhibits transition into
mitosis, as phosphorylated Cdc25C is not able to activate its
downstream targets and the cells become arrested at this
checkpoint. This arrest prevents DNA damaged cells to cycle
further and represents a survival mechanism that provides the
tumour cells the opportunity to repair their damaged DNA
(Houtgraaf et al, 2006). Therefore the reduction of phos-
phoCdc25C by enzastaurin, as detected by western blot analysis,
might explain the abrogation of the G2/M checkpoint and the
synergistic induction of apoptosis in the enzastaurin-pemetrexed
combination. Indeed, pemetrexed is able to damage the DNA
because of incomplete replication (Backus et al, 2000), which can
lead to arrest of the cells at the checkpoints controlling the cell
cycle. Thus, when combining these two agents, enzastaurin can
facilitate pemetrexed-damaged cells to undergo apoptosis. In line
with our observations, previous studies showed little effects of
enzastaurin alone on cell cycle progression (Lee et al, 2008), but
others reported that the non-selective PKC inhibitor UCN-01 was
able to inhibit the phosphorylation of Cdc25C and abrogate the
G2/M checkpoint, potentiating the cytotoxicity of a variety of
anticancer agents (Yu et al, 1998; Graves et al, 2000).
However, enzastaurin was also able to influence other proteins
involved in cell cycle regulation. In particular, the G1/S checkpoint
is, among other proteins, governed by the S-phase regulator E2F-1,
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swhose mRNA and protein expression was significantly reduced by
both enzastaurin and enzastaurin-pemetrexed treatment. These
results may be related to the inhibition of the Ras/MAPK/ERK-
dependent pathway, which is implicated in the modulation of the
expression of the cyclin D1 gene. Recent studies showed
controversial results on the effects of enzastaurin on ERK pathway
in different tumour cell lines (Guo et al, 2008; Lee et al, 2008).
However, cyclin D1 protein expression was reduced after 24h
exposure at IC50 values of UCN-01 (Akiyama et al, 1997) and cyclin
D1 downregulation results in E2F-1 inhibition (Kobayashi et al,
2006). Furthermore, UCN-01 induced the accumulation of under-
phosphorylated pRb (the dephosphorylated retinoblastoma pro-
tein form), which prevented the release of free E2F-1 (Akiyama
et al, 1997).
E2F-1 is a critical upstream transcriptional regulator of several
genes, including TS and DHFR (Li et al, 2006). Expression levels of
TS were associated with E2F-1 expression in NSCLC cells and
samples (Huang et al, 2007; Giovannetti et al, 2008).
Several studies showed that TS expression is significantly
correlated with pemetrexed sensitivity both in the preclinical and
in the clinical setting (Giovannetti et al, 2005; Gomez et al, 2006).
Therefore, the reduction of E2F-1 expression, leading to a
decreased amount of TS, can potentiate pemetrexed activity in
the enzastaurin-treated cells. TS, as an RNA-binding protein, also
regulates its own synthesis by impairing the translation of its
mRNA, whereas the binding to a specific inhibitor leads to
upregulation of TS protein (Chu et al, 1991). In agreement with
this hypothesis, as well as with the observed increase in TS mRNA
expression, as previously detected with pemetrexed and
5-fluorouracil (5-FU) (Peters et al, 2002; Mauritz et al, 2007), TS
protein expression in cell extracts was enhanced after pemetrexed
exposure. However, this study also shows that enzastaurin-
pemetrexed combination significantly inhibited the activity of
TS, potentially leading to synergistic drug interaction. These
results are in agreement with previous data demonstrating that
UCN-01 was able to enhance the activity of 5-FU through
downregulation of TS (Hsueh et al, 1998; Abe et al, 2000).
Enzastaurin also reduced the phosphorylation of the down-
stream PKCb-signaling pathway effectors Akt and GSK3b; these
findings are consistent with several previous reports in different
cancer cell lines, xenografts and peripheral blood mononuclear
cells (PBMCs) (Graff et al, 2005; Querfeld et al, 2006; Rizvi et al,
2006), suggesting the use of GSK3b phosphorylation in PBMCs as a
pharmacodynamic marker for enzastaurin (Graff et al, 2005). Our
experiments showed that the Akt pathway can also be affected by
pemetrexed, as reported previously (Giovannetti et al, 2005, 2008).
In addition, the enzastaurin-pemetrexed combination significantly
reduced Akt phosphorylation, which may explain the increased
apoptosis found in the pemetrexed-erlotinib combination in the
studied NSCLC cell lines.
Although recent preclinical studies have shown that enzastaurin
has a direct effect on several human cancer cells, tumour xenograft
models (Graff et al, 2005; Lee et al, 2008), and also patient-derived
tumour explants (Hanauske et al, 2007), enzastaurin was initially
developed for its striking antiangiogenic activity. In particular,
enzastaurin significantly decreased intratumoural vessels density
and VEGF expression in different human tumour xenografts
(Keyes et al, 2004). Similarly, a recent study showed a significant
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Figure 5 Antiangiogenic effects. Effects of pemetrexed, enzastaurin and their simultaneous combination on COX-2 expression (A), as detected by
western blot analysis, and on VEGF mRNA expression (B) and secretion in cell culture medium (C) of SW1573 and A549 cells, as detected by PCR and
ELISA assay, respectively. Columns (%), mean values obtained from three independent experiments; bars, s.e.; *Po0.05 with respect to control cells.
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sreduction of VEGF protein levels, as well as a reduction of VEGF
induction by radiotherapy, in the supernatants of glioma cells
exposed for 24h to enzastaurin (Tabatabai et al, 2007). Likewise in
our study enzastaurin significantly decreased both VEGF mRNA
expression and VEGF secretion into the medium. Furthermore,
despite the slight increase of VEGF expression induced by
pemetrexed, the enzastaurin-pemetrexed combination resulted in
a significant inhibition of VEGF expression, possibly leading to
reduced secretion of VEGF. The mechanism of this decrease was
postulated to be related to COX-2, as a strong correlation between
COX-2 and VEGF mRNA was reported in NSCLC patients (Yuan et al,
2005). However, in SW1573 no COX-2 expression was detected,
whereas in A549 cells COX-2 levels increased. Hence, VEGF decrease
might be related to other factors, as reported earlier in A549 xenograft
tumour tissues (Shaik et al, 2006). In a clinical study performed in our
institution enzastaurin reduced VEGF plasma levels (Peters et al, 2007).
However, a recent clinical trial in advanced NSCLC patients treated
with enzastaurin did not show a consistent change in plasma VEGF
levels, but low baseline VEGF levels were associated with longer
progression-free survival (Oh et al, 2008). Therefore, future studies are
warranted to determine whether VEGF levels can be used as a
predictive marker of the activity of enzastaurin alone or in combination
w i t ho t h e ra n t i c a n c e ra g e n t s .
Finally, other inhibitors of PKCs, such as staurosporine and its
analogue UCN-01, have the same properties as enzastaurin when it
comes to inhibition of the cell cycle, but are less selective than
enzastaurin. This non-selective inhibition of PKCs makes them too
toxic and hence their use in the clinical setting seems limited,
whereas enzastaurin which is a selective PKCb inhibitor, has
shown to be well-tolerated by patients in clinical trials (Carducci
et al, 2006; Oh et al, 2008).
In conclusion, enzastaurin is a very promising anticancer agent,
attacking several cellular signaling pathways that are involved in
the proliferation, cell cycle control, inhibition of apoptosis and of
pro-angiogenic properties of tumour cells. This makes it a good
candidate for different combination regimens, including combina-
tions with other novel targeted agents and cytotoxic drugs
commonly used in the clinical setting.
REFERENCES
Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M
(2000) UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cyto-
toxicity through down-regulation of thymidylate synthetase messenger
RNA. Jpn J Cancer Res 91: 1192–1198
Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T,
Okabe M, Akinaga S (1997) G1 phase accumulation induced by UCN-
01 is associated with dephosphorylation of Rb and CDK2 proteins
as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-
mutated human epidermoid carcinoma A431 cells. Cancer Res 57:
1495–1501
Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, Van
Groeningen CJ, Peters GJ (2000) Differences in the induction of DNA
damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Oncol Res 12: 231–239
Black JD (2000) Protein kinase C-mediated regulation of the cell cycle.
Front Biosci 5: D406–D423
Buter J, Giaccone G (2005) Medical treatment of non-small-cell lung cancer.
Ann Oncol 16(Suppl 2): ii229–ii232
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P,
Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS
(2006) Phase I dose escalation and pharmacokinetic study of enzastaurin,
an oral protein kinase C beta inhibitor, in patients with advanced cancer.
J Clin Oncol 24: 4092–4099
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relation-
ships: the combined effects of multiple drugs or enzyme inhibitors. Adv
Enzyme Regul 22: 27–55
Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S,
Allegra CJ (1991) Autoregulation of human thymidylate synthase
G1 S
G2 M
G2/M
Checkpoint
abrogated
ENZASTAURIN
Extracellular stimuli/growth factors
Intracellular signal transduction
Cell surface
Downregulation of
E2F-1 and TS
Promotes pemetrexed damaged
cells to undergo cell death
Enhances the
S-phase
effects and
cytotoxicity of
pemetrexed Downregulation
of pAkt
Downregulation
of pGSK3
Increases pemetrexed-
induced apoptosis
Downregulation
of VEGF
Prevents
angiogenesis,
reduces cell 
proliferation
Downregulation
of pErk1/2
Reduces cell 
proliferation
Figure 6 Molecular signaling pathways involved in the synergistic interaction of the PKCb inhibitor enzastaurin with pemetrexed. Enzastaurin enhanced
the growth inhibitory effects of pemetrexed through its pronounced anti-signaling effects downstream of PKCb. Moreover, the modulation of cell cycle
regulating proteins enhanced both apoptosis induction and pemetrexed-mediated TS enzyme inhibition.
Enzastaurin and pemetrexed in non-small cell lung cancer
C Tekle et al
757
British Journal of Cancer (2008) 99(5), 750–759 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
smessenger RNA translation by thymidylate synthase. Proc Natl Acad Sci
USA 88: 8977–8981
Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase
C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta
promotes cellular survival and chemotherapeutic resistance. Cancer Res
63: 780–786
Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M
(2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective
inhibitors of PKCbeta. Bioorg Med Chem Lett 13: 1857–1859
Fishman DD, Segal S, Livneh E (1998) The role of protein kinase C in G1
and G2/M phases of the cell cycle (review). Int J Oncol 12: 181–186
Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA,
Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular
mechanisms underlying the synergistic interaction of erlotinib, an
epidermal growth factor receptor tyrosine kinase inhibitor, with the
multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Mol Pharmacol 73: 1290–1300
Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M,
Danesi R (2005) Cellular and pharmacogenetics foundation of synergistic
interaction of pemetrexed and gemcitabine in human non-small-cell lung
cancer cells. Mol Pharmacol 68: 110–118
Goekjian PG, Jirousek MR (2001) Protein kinase C inhibitors as novel
anticancer drugs. Expert Opin Investig Drugs 10: 2117–2140
Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer
NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR (2006) A phase II
trial of pemetrexed in advanced breast cancer: clinical response
and association with molecular target expression. Clin Cancer Res 12:
832–838
Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN,
Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM,
Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D
(2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin
(LY317615.HCl), suppresses signaling through the AKT pathway, induces
apoptosis, and suppresses growth of human colon cancer and
glioblastoma xenografts. Cancer Res 65: 7462–7469
Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O’Connor PM, Piwnica-
Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory
pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:
5600–5605
Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, Chen J, Sun Q, Lu W, Kang X,
Chen P (2008) Involvement of protein kinase C beta-extracellular signal-
regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock
protein 27 activation in hepatocellular carcinoma cell motility and
invasion. Cancer Sci 99: 486–496
Hanauske A, Weigang Koehler K, Yilmaz E, Graefe T, Kuenen B, Thornton
D, Lahn M, Darstein C, Musib L, Giaccone G (2006) Comparison of
enzastaurin pharmacokinetics and safety in the once daily (QD) and
twice daily (BID) dose regimens: A phase I study. ASCO Annual Meeting
Proceedings 2006. J Clin Oncol 18S: 2047
Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium:
a novel antifolate clinically active against multiple solid tumors.
Oncologist 6: 363–373
Hanauske AR, Oberschmidt O, Hanauske-Abel H, Lahn MM, Eismann U
(2007) Antitumor activity of enzastaurin (LY317615.HCl) against
human cancer cell lines and freshly explanted tumors investigated in
in-vitro (corrected) soft-agar cloning experiments. Invest New Drugs 25:
205–210
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J,
Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K,
Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr
PA (2004) Randomized phase III trial of pemetrexed vs docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol 22: 1589–1597
Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L,
Melnyk O, Ramies D, Lin M, Sandler A (2007) Phase II study of efficacy
and safety of bevacizumab in combination with chemotherapy or
erlotinib compared with chemotherapy alone for treatment of recurrent
or refractory non small-cell lung cancer. J Clin Oncol 25: 4743–4750
Houtgraaf JH, Versmissen J, van der Giessen WJ (2006) A concise review of
DNA damage checkpoints and repair in mammalian cells. Cardiovasc
Revasc Med 7: 165–172
Hsueh CT, Kelsen D, Schwartz GK (1998) UCN-01 suppresses thymidylate
synthase gene expression and enhances 5-fluorouracil-induced apoptosis
in a sequence-dependent manner. Clin Cancer Res 4: 2201–2206
Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H
(2007) E2F1 overexpression correlates with thymidylate synthase and
survivin gene expressions and tumor proliferation in non small-cell lung
cancer. Clin Cancer Res 13: 6938–6946
Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D,
Chen YF, Iversen P, Teicher BA (2004) LY317615 decreases plasma VEGF
levels in human tumor xenograft-bearing mice. Cancer Chemother
Pharmacol 53: 133–140
Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM,
Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B (2006)
Transcriptional profiling identifies cyclin D1 as a critical downstream
effector of mutant epidermal growth factor receptor signaling. Cancer
Res 66: 11389–11398
Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G
(2006) Immunohistochemical detection of protein kinase C-beta (PKC-
beta) in tumour specimens of patients with non-small cell lung cancer.
Histopathology 49: 429–431
Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im
SA, Kim TY, Kim WH, Bang YJ (2008) Enzastaurin, a protein kinase C
beta inhibitor, suppresses signaling through the ribosomal S6 kinase and
bad pathways and induces apoptosis in human gastric cancer cells.
Cancer Res 68: 1916–1926
Li W, Xu RJ, Zhang HH, Jiang LH (2006) Overexpression of cyclooxy-
genase-2 correlates with tumor angiogenesis in endometrial carcinoma.
Int J Gynecol Cancer 16: 1673–1678
Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP (2004) Protein
kinase CbetaII regulates its own expression in rat intestinal epithelial cells
and the colonic epithelium in vivo. JB i o lC h e m279: 45556–45563
Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ
(2007) Thymidylate synthase and dihydropyrimidine dehydrogenase
mRNA expression after administration of 5-fluorouracil to patients with
colorectal cancer. Int J Cancer 120: 2609–2612
Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen V, Ma D, Bunn
PA (2006) Enzastaurin a protein kinase Cbeta-selective inhibitor, inhibits
the growth of SCLC and NSCLC cell lines. ASCO Annual Meeting
Proceedings 2006. J Clin Oncol 18S: 13138
Oberschmidt O, Eismann U, Schulz L, Struck S, Blatter J, Lahn MM, Ma D,
Hanauske AR (2005) Enzastaurin and pemetrexed exert synergistic
antitumor activity in thyroid cancer cell lines in vitro. Int J Clin
Pharmacol Ther 43: 603–604
Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G (2008)
Enzastaurin, an oral serine/threonine kinase inhibitor, as second-
or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26:
1135–1141
Peters GJ, Backus HH, Freemantle S, van TB, Codacci-Pisanelli G, van der
Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E,
Meijer S, Jansen G, van Groeningen CJ, Pinedo HM (2002) Induction of
thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim
Biophys Acta 1587: 194–205
Peters GJ, Hooiberg JH, Kaspers GJL, Jansen G (2005) Folates and
antifolates in the treatment of cancer; role of folic acid supplementation
on efficacy of folate and non-folate drugs. Trends in food science and
technology 16: 289–297
Peters GJ, Tekle C, Kuenen B, Honeywell RJ, Sigmond J, Giovannetti E,
Hanauske AR, Lahn M, Giaccone G (2007) A translational study on
the protein kinase C-b inhibitor enzastaurin and the thymidylate
synthase inhibitor pemetrexed. AACR Annual Meeting Proceedings
2007, abstract 1820
Peters GJ, Van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM,
Ackland SP (2000) Basis for effective combination cancer chemotherapy
with antimetabolites. Pharmacol Ther 87: 227–253
Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK,
Munshi N, Hideshima T, Chauhan D, Anderson KC (2007) Targeting
PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally
available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood
109: 1669–1677
Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS,
Krett NL, Rosen ST (2006) The selective protein kinase C beta inhibitor
enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines
through the AKT pathway. J Invest Dermatol 126: 1641–1647
Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R,
Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N,
van Hal G, Beijnen JH, Schellens JH, Voest EE (2007) Phase I
pharmacokinetic and pharmacodynamic study of the oral protein kinase
Enzastaurin and pemetrexed in non-small cell lung cancer
C Tekle et al
758
British Journal of Cancer (2008) 99(5), 750–759 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sC beta-inhibitor enzastaurin in combination with gemcitabine and
cisplatin in patients with advanced cancer. Clin Cancer Res 13: 4474–4481
Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL,
Rosen ST (2006) Enzastaurin (LY317615), a protein kinase Cbeta
inhibitor, inhibits the AKT pathway and induces apoptosis in multiple
myeloma cell lines. Mol Cancer Ther 5: 1783–1789
Rots MG, Pieters R, Peters GJ, van Zantwijk CH, Mauritz R, Noordhuis P,
Willey JC, Hahlen K, Creutzig U, Janka-Schaub G, Kaspers GJ, Veerman
AJ, Jansen G (1999) Circumvention of methotrexate resistance in
childhood leukemia subtypes by rationally designed antifolates. Blood
94: 3121–3128
Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to
cancer therapy. J Clin Oncol 23: 9408–9421
Shaik MS, Chatterjee A, Jackson T, Singh M (2006) Enhancement of
antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer
118: 396–404
Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ
(2003) Induction of resistance to the multitargeted antifolate Pemetrexed
(ALIMTA) in WiDr human colon cancer cells is associated with
thymidylate synthase overexpression. Biochem Pharmacol 66: 431–438
S p a l d i n gA C ,W a t s o nR ,D a v i sM E ,K i mA C ,L a w r e n c eT S ,B e n - J o s e fE( 2 0 0 7 )
Inhibition of protein kinase Cbeta by enzastaurin enhances radiation
cytotoxicity in pancreatic cancer. Clin Cancer Res 13: 6827–6833
Tabatabai G, Frank B, Wick A, Lemke D, von Ku ¨rthy G, Obermuller U,
Heckl S, Christ G, Weller M, Wick W (2007) Synergistic antiglioma
activity of radiotherapy and enzastaurin. Ann Neurol 61: 153–161
Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt
overexpression and loss of PTEN expression in non-small cell lung
cancer confers poor prognosis. Lung Cancer 51: 181–191
Temmink OH, Prins HJ, van Gelderop E, Peters GJ (2007) The Hollow Fibre
Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in
colon cancer cells. Br J Cancer 96: 61–66
Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C,
Mendelsohn LG (1997) Cell cycle effects of antifolate antimetabolites:
implications for cytotoxicity and cytostasis. Cancer Chemother
Pharmacol 39: 521–531
Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG (1999) Cell cycle
modulation by a multitargeted antifolate, LY231514, increases the
cytotoxicity and antitumor activity of gemcitabine in HT29 colon
carcinoma. Cancer Res 59: 3671–3676
van Triest B, Loftus BM, Pinedo HM, Backus HH, Schoenmakers P,
Telleman F, Tadema T, Aherne GW, van Groeningen CJ, Zoetmulder FA,
Taal BG, Johnston PG, Peters GJ (2000) Thymidylate synthase expression
in patients with colorectal carcinoma using a polyclonal thymidylate
synthase antibody in comparison to the TS 106 monoclonal antibody.
J Histochem Cytochem 48: 755–760
van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F,
Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G,
Peters GJ (1999) Thymidylate synthase level as the main predictive
parameter for sensitivity to 5-fluorouracil, but not for folate-based
thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
Clin Cancer Res 5: 643–654
Yu BZ, Zheng J, Yu AM, Shi XY, Liu Y, Wu DD, Fu W, Yang J (2004) Effects
of protein kinase C on M-phase promoting factor in early development of
fertilized mouse eggs. Cell Biochem Funct 22: 291–298
Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini
R, Watanabe N, Piwnica-Worms H, O’Connor PM (1998) UCN-01
abrogates G2 arrest through a Cdc2-dependent pathway that is associated
with inactivation of the Wee1Hu kinase and activation of the Cdc25C
phosphatase. J Biol Chem 273: 33455–33464
Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, Yang PC (2005) Total
cyclooxygenase-2 mRNA levels correlate with vascular endothelial
growth factor mRNA levels, tumor angiogenesis and prognosis in non-
small cell lung cancer patients. Int J Cancer 115: 545–555
Enzastaurin and pemetrexed in non-small cell lung cancer
C Tekle et al
759
British Journal of Cancer (2008) 99(5), 750–759 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s